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Abstract
Background: The aim of this open-label, randomized controlled trial conducted in four African countries (Madagascar,
Niger, Central African Republic, and Senegal) is to compare three strategies of renutrition for moderate acute malnutrition
(MAM) in children based on modulation of the gut microbiota with enriched flours alone, enriched flours with prebiotics
or enriched flours coupled with antibiotic treatment.
Methods: To be included, children aged between 6 months and 2 years are preselected based on mid-upper-arm
circumference (MUAC) and are included based on a weight-for-height Z-score (WHZ) between − 3 and − 2 standard
deviations (SD). As per current protocols, children receive renutrition treatment for 12 weeks and are assessed weekly to
determine improvement. The primary endpoint is recovery, defined by a WHZ≥− 1.5 SD after 12 weeks of treatment.
Data collected include clinical and socioeconomic characteristics, side effects, compliance and tolerance to interventions.
Metagenomic analysis of gut microbiota is conducted at inclusion, 3 months, and 6 months. The cognitive development
of children is evaluated in Senegal using only the Developmental Milestones Checklist II (DMC II) questionnaire at
inclusion and at 3, 6, and 9 months. The data will be correlated with renutrition efficacy and metagenomic data.
Discussion: This study will provide new insights for the treatment of MAM, as well as original data on the modulation of
gut microbiota during the renutrition process to support (or not) the microbiota hypothesis of malnutrition.
Trial registration: ClinicalTrials.gov, ID: NCT03474276 Last update 28 May 2018.
Keywords: Moderate acute malnutrition, Prebiotic, Azithromycin, Microbiota, Metagenomic
Background
The main objective of this study is to improve the nutrition
strategy used to treat moderate acute malnutrition (MAM).
This is based on modulation of the gut microbiota with an
adjunct product added to standard nutrition flours.
Undernutrition in Africa
Child malnutrition in intertropical zones is a major public
health problem. It favors the appearance of diarrhea but
can also (1) disrupt the response to infection [1], (2) lead
to an imbalance of the commensal flora and inflammation
[2], and (3) modulate the response to vaccines [3]. These
changes may also alter the cognitive development of chil-
dren. Due to its life-threatening impact, programs provide
care mainly for severe acute malnutrition (SAM), which is
frequent in disturbed political contexts such as the Central
African Republic (CAR) or during crop failure related to
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drought, like in Sahel. For example, in Niger, Action Contre
la Faim Network (ACF) had to deal with 400,000 cases of
SAM in 2013. However, aside from the emergency situ-
ation, SAM can develop in a context of chronic malnutri-
tion (CM), such as in Madagascar, where 47.4% of children
aged under 5 years are stunted [4]. MAM often happens
during the first years of life when food is introduced in
complement to breast milk. It can be managed at home
and not at the hospital. However, if the management of the
MAM changes over the last 30 years, the composition of
flours has remained virtually unchanged. Indeed the time
to recover is still long, and the percentage of success can be
low [5], with high default rates or nonresponse to
treatment, low coverage, and high associated costs [6–8].
Malnutrition and microbiota
Related to poverty and poor access to sanitation, infectious
diseases are responsible for 25% of deaths worldwide, and
diarrhea is the third deadliest infection, with approximately
525,000 per year for children aged under 5 years [9, 10].
Diarrhea can modulate gut microbiota [11, 12] but an
effect of an imbalance in the gut microbiota, regardless of
diarrhea, on long-term child growth can also be important.
This gut microbiota accounts for approximately 1012 mi-
croorganisms in humans, including bacteria, archae, yeast,
viruses, and parasites. Gut microbiota can establish early in
a child’s life (may be even during pregnancy and delivery)
and it can modulate diseases [13]. It changes greatly with
the introduction of food [14]. Its composition also varies
between industrialized and low/middle-income countries
(LMICs) with an increased abundance of Prevotella species
in developing countries compared to an increased abun-
dance of Bacteroides in developed countries. [15–17]. In
LMICs, urease-positive strains are enriched, indicating
adaptations to the low-protein food that is consumed [17].
Recent studies have shown a link between SAM and the
colonic microbiota composition [18–24]. During the first
years of life, children with SAM have a significant delay in
the maturation of the microbiota [23]. Changes in micro-
biota composition lead to “dysbiosis,” marked by the en-
hancement of gut permeability and inflammation [25, 26].
Indeed, chronic inflammation induced by permanent
stimulation due to food heavily contaminated by nonpatho-
genic or pathogenic bacteria could associated with villous
atrophy, anorexia and malnutrition. These changes in
microbiota could be a decrease in diversity or a shift in its
composition as described in acute gastrointestinal infection
[27, 28], inflammatory bowel disease [29, 30], coeliac
disease [31–35], colon and liver cancer [36, 37], obesity
[38], and diabetes [39].
The microbiota of non-stunted children looks
enriched in probiotic species Bifidobacterium longum
and Lactobacillus mucosae, whereas that of stunted chil-
dren was enriched in inflammogenic taxa, including
those in the genus Desulfovibrio and the order Campylo-
bacterales [40]. Along the same line of reasoning, the
metabolic impact of parasites such as Isospora belli, Cy-
clospora, Cryptosporidium, and Microsporidia in mal-
nourished persons seems largely underresearched, but
Giardia was recently associated with malnutrition [41].
During malnutrition, the disturbance of immunity may
alter the response to vaccines, especially those adminis-
tered orally (poliovirus, rotavirus, etc.) [2, 3]. This reduced
efficacy was confirmed during severe malnutrition, but is
still being debated regarding moderate and chronic
malnutrition. The impact of microbiota on brain function
is also a major focus of research [42–46].
How to modulate the microbiota: antibiotics versus
prebiotics
In malnourished children, clinical signs of infection can
be attenuated. Indeed, the WHO recommends treatment
of severely malnourished children with antibiotics [47].
Compared to standard flours, an increase in weight gain
was described for children treated with flours + antibi-
otics [48]. In Malawi, a short-term effect of antibiotics
on the nutritional recovery rate and mortality rate was
confirmed for children with SAM [49, 50]. In Malawi,
no effect of rifamixin on intestinal permeability was ob-
served [49], whereas in Niger (Epicentre study), amoxi-
cillin did not show any short-term benefit on the
recovery rate of SAM compared with placebo [51]. How-
ever, hospital transfer rates decreased significantly. In
Kenya, cotrimoxazole also failed to improve the clinical
status of children with SAM [52]. The antibiotics can
destroy gut microflora, but the effect on intestinal
barrier integrity is still being debated [53].
Antibiotics can also restore equilibrium between the bac-
terial population induced by pathogenic bacteria. This has
been described in the case of cholera, as a vibrio infection,
and it results in a decrease in Bacteroidetes, Firmicutes,
and Actinobacteria and an increase in harmful Proteobac-
teria. This disequilibrium was approached with treatment
with macrolides; the abundance of Escherichia coli, Entero-
coccus, and Veillonella increased, while that of Bifidobac-
teria, Bacteroides, and Ruminococcus decreased [54].
However, the use of antibiotics for SAM children, even
though recommended by the WHO, remains debated
[55–59] both for its efficacy and for the possible increase
in drug resistance [60]. To date, no trials have been
performed on antibiotic use among MAM children.
Firmicutes and other common gut microorganisms can
contribute to fight by themselves against pathogens by
local production of bacteriocins [61].
In the MALINEA (Malnutrition et Infection de l’Enfance
en Afrique) protocol, macrolides were chosen to treat
MAM based on (1) a narrower antibacterial spectrum of
activity than other widely used antibiotics, (2) a rare use in
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dispensaries, especially as first-line treatment, which will
prevent the emergence of resistant strains during mass ad-
ministration, and (3) a favorable side-effect profile [62].
The main side effect of macrolides is gastrointestinal dis-
turbance, which is less prevalent with azithromycin than
with clarithromycin. For azithromycin, a long half-life and
activity allows a 3-day treatment with a single daily dose
(20 mg/kg/day). Anti-inflammatory and immunomodula-
tory activities have also been reported. A benefit was also
reported on neonatal growth when given to the mother
[63]. In line, the recent MORDOR trial [64] showed the
benefit of azithromycin alone on the mortality and clinical
status of children.
Microbiota can also be modulated through several very
different compounds called probiotics [65], prebiotics,
and milk oligosaccharides [66]. Microbiota transplant-
ation can also be used but is still experimental [67].
For probiotics (a specific strain of bacteria inoculated
orally to the patient), the choice of species and, even
more, the choice of strain to use, are very important and
remain pitfalls for clinical trials [68]. The benefit of com-
bination of probiotics + prebiotics can also be ques-
tioned, as in the PRONUT study [69].
On the other hand, prebiotics are mostly nondigestible
carbohydrates, which serve as substrates, and they sup-
port proliferation of certain bacteria, such as bifidobac-
teria and lactobacilli. Early in life, they are provided by
maternal milk through breast-feeding at the same time
as commensal bacteria [70].
Unlike antibiotics, prebiotics do not modify the existing
strains of bacteria but impact the proportions of the differ-
ent groups of bacteria in the intestine (gut microbiota). The
best-known prebiotics are (1) fructans (fructose polymers
including inulin), which are present in many plants and ex-
tracted from chicory tubers [71], (2) fructo-oligosaccharides
(FOS), obtained by hydrolysis of inulin or by biosynthesis
from sucrose, and (3) fructose/galactose-containing oligo-
saccharides (galacto-oligosaccharides, GOS), which are
natural products of human breastmilk. In children, most
studies have used combinations of inulin and GOS [72].
Depending on the microbiota, they reach more or less
distal parts of the colon before being metabolized by the
resident bacteria [73, 74]. Prebiotics have been associated
in several studies with profound changes in the microbial
ecology of the gut and in a shift towards “healthier”
communities [75]. Many studies have been conducted in
animals and in human adults [76], and recent studies sup-
port a beneficial effect for HIV-infected children. In studies
performed so far using the prebiotic inulin, the proportion
of Lactobacillus spp., Bifidobacterium spp. [77, 78], and
Faecalibacterium prausnitzii [75, 79, 80] was shown to be
increased during treatments, while the growth of Entero-
bacteriaceae and Clostridium spp. seemed to be restricted
[78, 80, 81]. Prebiotics seemed to modulate lymphoid tissue
associated with the intestine, resulting in improvement of
inflammatory bowel symptoms in children or post-vaccine
responses against measles [82–85]. Inulin consumption
may improve the absorption of minerals in the colon, such
as calcium, magnesium, zinc, and iron [86–88].
Cognitive impairment
Malnutrition is frequently associated with cognitive
delay, compromising child development and education
[89, 90]. An effect of the modulation of microbiota in
the development of cognitive function in children can be
suspected [91, 92]. Deworming by itself can affect the
cognitive skills of children [93] but this could be due to
an indirect effect on iron and anemia. The opportunity
for modulating the intestinal microbiota, diarrhea or
cognitive development with pre- or probiotics is also
under study [94–97].
Malnutrition is a major health problem in the four
countries involved in the project
The choice of the four countries in which to conduct this
research is based on epidemiological data on moderate
malnutrition, on existing facilities supported by ACF in
the field and on the ability to perform high-level biological
analysis in local laboratories. The countries selected in this
project are particularly vulnerable to malnutrition and
diarrhea. Programs are supported either by local facilities
or through nongovernmental organizations (NGOs),
especially ACF.
In Madagascar [4], acute malnutrition affects 8.6% of
children aged under 5 years, including 1.4% with severe
forms. At weaning, the majority of children benefit from
the introduction of food supplements but have a poorly
diversified diet. Growth retardation begins in utero (13%
of children weigh less than 2.5 kg at birth) and increases
at 12 months of age. Micronutrient deficiency is also a
major public health problem in Madagascar that could
increase the risk of morbidity and mortality [4].
In Niger, global acute malnutrition (GAM) has
remained above the alert threshold (10%) in recent years
among children aged 6–59 months. For children aged 6
to 23 months, malnutrition regularly exceeds the emer-
gency threshold of 15%, as in 2005, 2010 (22%), and
2011 (20.2%). During the last 5 years, chronic malnutri-
tion (CM) or growth retardation affected one of every
two children in the country [97]. The overall under-
weight (weight- for-age) prevalence ranged between 32
and 40% over the past 5 years [98–101].
In 2014, in Senegal, the prevalence of GAM at the na-
tional level was 8.8%. The prevalence in some depart-
ments, such as Ranérou, Podor, and Kanel, exceeds the
critical threshold of 15%. Sixteen departments of 45 have
exceeded the threshold of 10% GAM. Chronic malnutri-
tion affects 15.5% of children aged 0–59 months [102].
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In the CAR, in 2012, at a national level, the GAM
prevalence rate was 8%, and the SAM rate was 1.9%.
The CM rate was 38.7% [103, 104]. In addition to the
progressive reopening of nutrition centers, mobile clinics
are organized to screen children among the displaced in
Bangui (639,000 displaced people; i.e., 12% of the total
population) [105]. The country is in crisis, and only
NGO interventions cover these emergencies [106].
Methods and design
The aim
The aim of this project is to define an easy-to-use modi-
fied strategy of renutrition to use in primary health centers
to treat MAM before it degenerates into SAM. The main
problem to tackle is that, in a peri-urban context, alimen-
tation of small children is difficult to manage accurately,
especially when food (or financial) resources are limited.
The objectives
The general objective of this project is to improve nutrition
for children with moderate malnutrition using strategies to
modulate intestinal microbiota. The objective of this
three-arm, open-label, randomized multicountry study is to
evaluate the effectiveness of two improved strategies of
management of MAM in children aged between 6 months
and 2 years in comparison with a reference standard of
care. Recovery is defined by a (weight-for-height Z-score)
WHZ ≥ − 1.5 standard deviations (SD) after 3 months of
treatment.
The secondary objectives are (1) to compare, for each
group, all the measurements before and 3 months after
intervention (weight, length, mid-upper-arm circumfer-
ence (MUAC)); (2) to compare, between the three
groups, the occurrence of clinical outcomes (intercur-
rent illness, hospitalization and transfer to the next level
of care), the compliance to protocol, and tolerance (re-
ported adverse and side effects, duration and intensity);
and (3) to analyze the gut microbiota of the children
during the renutrition process. In Senegal, psychomotor
development will be assessed at inclusion and 3, 6, and
9 months after intervention using the DMC II (Develop-
mental Milestones Checklist). DMC II scores will be
compared (1) for the same child before and after inter-
vention, (2) at inclusion between matched healthy chil-
dren and malnourished ones from the same district, and
(3) between arms at 3, 6, and 9 months.
The study design (protocol version 2_ 28 February 2018)
According to centralized randomization, the children
will receive one of the following:
Arm 1 (control): malted milk Prise en Charge de la
MAM (PEC-MAM) flour + antiparasitic (albendazole)
Arm 2 (antibiotic): malted milk PEC-MAM flour +
antiparasitic (albendazole) + azithromycin for 3 days
Arm 3 (prebiotic): malted milk PEC-MAM flour +
antiparasitic (albendazole) + inulin/FOS mixed with
flour
A control group of well-nourished children without diar-
rhea aged 18 to 24 months will also be included to match
the malnourished ones but without follow-up visits. The
objective is to investigate microbiota of well-nourished
children living in the same place and at the same time as
the case group, to take into account local and seasonal
variation of the microbiota. As only one stool sample will
be obtained from non-stunted children, children under
18 months will not be included to discard the fluctuating
composition of the microbiota at such young ages.
Participants and enrollment
In Niger, the study will be conducted in the department
of Mayahi, in the municipalities of Tchake and Issa-
wanne. In Tchake, the total population is 28,338 inhabi-
tants, with 5668 children aged less than 5 years, and in
Issawanne, the total population is of 45,152 inhabitants,
with 9030 children aged under 5 years.
In Senegal, recruitment will be conducted in the district
of Guédiawaye, near Dakar. The district is a low-income
area of 355,525 inhabitants, with an average rate of MAM
of 6%. The primary health care center will be Hamo V,
where an average of 500 MAM cases are followed each
semester. A large team of community relay agents, led by
nurses from the primary health care center, is in charge of
the screening of MAM in the community.
In Madagascar, the study will take place in poor neigh-
borhoods of Antananarivo. Two different structures run
by local NGOs (CRENAM Andohotapenaka) and Centre
de Santé Mitia are dealing with malnourished children.
In the CAR, the study will take place in Bangui in two
private centers that support MAM: the St. Jacques and
the St. Joseph’s Health Centres. These centers are
supported by the World Food Program, which provides
nutritional supplements.
Prescreening of malnourished children aged between 6
and 24 months will be conducted in the country by com-
munity health workers using arm circumference (115 ≤
MUAC < 130 mm). To be definitively included, children
should have a WHZ between − 3 and − 2 SD, and should
be followed for at least 3 months. Written consent from
the parents or legal guardians will be obtained. Children
not satisfying these criteria will not be included, nor will
those (1) with complications requiring intensive clinical
care (severe vomiting, hypothermia < 35 °C or fever > 39 °
C, pneumonia, and severe anemia), (2) with extensive in-
fections, (3) who are weak, apathetic or unconscious, and
(4) or presenting fitting/convulsions, severe dehydration
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or any condition that requires an infusion or tube feeding.
Children currently receiving one of the following treat-
ments will also be excluded from entering the study:
antacids, cetirizine, digoxin, ergotamine, zidovudine. More-
over, those with hypersensitivity to macrolides, flour or the
prebiotics used during the study will also be excluded. HIV
testing is not planned as its prevalence is very low in three
countries out of four. For CAR systematic testing of young
children for HIV was considered as a stigmatization of the
mother by the National Ethic Committee which will induce
refusal of the mothers to participate.
Recruitment, randomization, and follow-up (Fig. 1 and
Additional file 1)
The enrollment will take place at the primary health
center after weight and height assessment, signature of
written consent from the parent or legal guardian, and
verification of inclusion/exclusion criteria.
Randomization will be stratified by country, health
center, and age (6–11 months versus 12–24 months).
Randomization will be achieved in a 1:1 ratio using ran-
dom permutation blocks. A clinical examination will be
done, and stool samples will be collected. Systematic
treatment with albendazole will be given to all children
in the three arms aged older than 12 months after col-
lection of the stools. For children treated with azithro-
mycin, the first treatment will be given after stool
collection at the dispensary. Doses for the following 2
days will be given at the health center as well.
After enrollment, in Senegal, children with MAM will
be evaluated for cognitive development and ability, with
a DMC II (Developmental Milestones Checklist) ques-
tionnaire applied by a trained social worker.
Children will be followed up weekly for 12 weeks and
at 6 months (M6) at the health center. At each visit, (1)
flours will be given to the caretaker for the whole week,
(2) weight, height, and arm circumference will be
assessed, and (3) a clinical examination will be carried
out, and data on safety and child’s food consumption
will be investigated. In the case of a missing visit or in-
sufficient weight gain, a visit at home will be organized
by health workers to collect supplementary information.
At inclusion, 3 months (M3) and 6 months (M6), stool
samples will be collected. After 6 months, the follow-up
will be stopped except for in children involved in the
psychomotor development evaluation protocol, who will
be followed until age 9 months (M9). However, in the
case of nonrecovery at M3, children will still receive
follow-up care according to the national recommenda-
tions but will be considered “treatment failure.”
Interventions
Supplementary feeding
Default of quality of flours obtained from the local market
in African countries is a very common pitfall that is poorly
addressed by NGOs. For the trial, flours will be produced
by an industrial partner (PROTEIN KISSEE LA Zone indus-
trielle, Vridi, Port-Bouet, 18 BP 2335 Abidjan). It is a
well-established brand on the West African market provid-
ing ready-to-eat fortified complementary foods. The com-
position of the flours, described in Table 1, will be adapted
to the international malted milk PEC-MAM standard [107].
Antibiotics
A vial of powder for oral suspension of azithromycin
(600 mg) will be restored at 200 mg/5 mL and then
given with a syringe for oral administration three times
Enrolment Follow -up
Enrolment
Enrolment J0 J1 J2
Weekly visit 
(W1 to W11)
Final visit 
(W12)
Supplementary visit 
(no recovery at W12)
Control visit 
(M6)
Control visit 
(M9)*
Close-out
Information /consent X
Inclusion criteria X
Pre-inclusion X
Treat assignment X
Interventions
Clinical examination X X X X X
Anthropometric data X X X X X
Stool sampling X X X
Cognitive assessment* X X X X
Flours X X X X
albendazole X
Arm 2 Azithromycin X X X
Arm 3 Prebiotic X X X X
Compliance checking X X X X X
Side effect registration X X X X X
quantity of food used X X X X X
Assessments
Monitoring X X X X X X X X X
Audit
Site supervision
(*Senegal)
Fig. 1 Timetable of the follow up of the children
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once a day over a maximum of 4 days (in case of 1 day
missing) (20 mg/kg/day daily for 3 days). The same
batch of antibiotics will be used in the four countries.
Prebiotics
The recommended doses with positive effects on the in-
testinal flora are between 2.5 to 10 g/day [108, 109]. The
main side effects are observed with doses more than
40 g/day, as the substances can cause bloating and in-
duce intestinal cramps. Abdominal pain has been re-
ported with doses of 10 g/day. For this study, we will
evaluate the effectiveness of a combination of prebiotic
inulin / FOS (Synergy1 6 g/day if age ≥ 12 months and
4 g/day if < 12 months), as it is simple to be obtained
(manufactured by BENEO, Tienen, Belgium) and is ac-
tive at different levels of the digestive tract.
Data collection
Clinical data
At inclusion, a standardized questionnaire will be con-
ducted with the parents or legal guardians to collect
general characteristics, socioeconomic and clinical data.
At each visit, clinical assessment will be recorded until
recovery and then at M6, data will be registered con-
cerning undercurrent illness, signs of infections (diar-
rhea, vomiting, fever, cough), need to transfer to
hospital, and safety and adherence to treatments (de-
fined as completion of all 7 days of the study regimen).
Anthropometric data
The children will be monitored weekly for 3 months (or
until recovery if treatment fails) at the primary health cen-
ter. One additional visit is planned at 6 months. At each
visit, weight, length, and MUAC will be measured. Bal-
ances will be from SECA UNICEF (± 100 g). Length will
be measured on children placed in an elongated position
using a Fathom Infant / Child ShorrBoard for infants aged
less than 2 years (130 cm with graduations of 0.1 cm).
MUAC will be measured with a UNICEF MUAC tape.
Laboratory processes
Stool samples will be collected during the day and stored at
4 °C until transportation to the laboratory. At laboratory,
stools will be separated in aliquots and stored at − 80 °C
until analysis. Stool examination will be based on metage-
nomic approaches. Whole deoxyribonucleic acid (DNA)
will be extracted from stools using a procedure adapted for
stools including bead fractioning and a QIAGEN stool ex-
traction kit. Fragments of the 16S gene will be polymerase
chain reaction (PCR) amplified using V3/V4-adapted
primers. Sequencing of the PCR products will be carried
out on a Miseq Illumina machine. Metagenomic analysis
will be conducted using the SHAMANN package. In paral-
lel, direct detection of pathogens (Salmonella, STEC,
Campylobacter, Vibrio cholerae, V parahaemolyticus, V
vulnificus, Cryptosporidium sp., Entamoeba histolytica,
Giardia lamblia, Microsporides sp., Adenovirus, Astro-
virus, Norovirus, Rotavirus) will be done using specific
quantitative-PCR (Q-PCR) and ELISA protocols in the
Institut Pasteur de Madagascar, Institut Pasteur de Dakar,
and Institut Pasteur de Bangui.
Cognitive and motor development
During this study, a Developmental Milestones Checklist
II (DMC II) questionnaire will be administered to par-
ticipating children to evaluate their cognitive and motor
abilities. This questionnaire is adapted to children aged
between 1 and 59 months and has been developed spe-
cifically to be used in developing countries and particu-
larly in sub-Saharan Africa.
In Senegal, the DMC II will be applied during enroll-
ment at inclusion and 3, 6, and 9 months, after enroll-
ment. Eighty children with MAM and 80 healthy
non-stunted children will be included in this specific
phase. This questionnaire has already been used in several
countries (Kenya, Bukina Faso, Mali). It can be applied by
Table 1 Composition of the flours
Without prebiotics With prebiotics
Composition (% of dry weight)
wheat 62.4% 60.9%
soya 20.8% 20.3%
sugar 8% 8%
dry milk 7% 7%
iodinated salt 0.2% 0.2%
vitamins and salts 1.3% 1.3%
flavor 0.4% 0.4%
Prebiotic 0% 2%
Total 100% 100%
Overall composition of the flour and additional compounds (for both
with and without prebiotic): composition per 100 g of flour
calories (kcal) 420 ascorbic acid 60
protein total (g) 15 thiamin 1
lipids (g) 9 riboflavin 1
carbohydrates 66 nicotinamide (mg) 12
fibers 2 folic acid (mg) 0.3
sodium (mg) 200 pantothenic acid (mg) 4
calcium mg) 266 biotin (μg) 0.016
phosphorus (mg) 200 vitamin E (IU) 10
potassium (mg) 610 vitamin B12 (μg) 1.8
iron (mg) 23.2 vitamin A (IU) 2668
copper (mg) 0.18 vitamin D (IU) 400
zinc (mg) 16.6 vitamin B6 (mg) 1
manganese (mg) 2.4
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trained but unspecialized field workers and is fast to docu-
ment (20–30 min). Adaptation of the questionnaire to the
local context will be done during a preliminary study con-
ducted at the Children’s Hospital of Dakar.
Evaluation criteria
The primary endpoint is recovery, defined by WHZ> − 1.5
SD at two successive examinations without hospitalization
or undercurrent discharge to SAM or lost to follow-up. The
main endpoint will be at 3 months. This is a stronger criteria
of recovery than usual (WHZ>− 2), which avoids misclassi-
fication of the children at the end of the intervention.
Secondary outcomes include anthropometric parameters
(weight, length, and MUAC), time for recovery, and safety
of the strategy, compliance to treatment and psychomotor
development evolution (for Senegalese children).
The main biological secondary endpoint is to analyze
the variations of microbiota and the presence of specific
pathogens during the renutrition process. The major
question is to understand if microbiota differ between
well- and malnourished children and if renutrition retard-
ation is related to a specific type of microbiota. Microbiota
will be expressed as Operational Taxonomic Units
(OTUs), and the results of Q-PCR as positive/negative.
Statistical considerations
Full details on data management and the database can
be available on reasonable request to the corresponding
author. Databases and confidentiality purposes were
already approved by either the National Ethics Commit-
tees, the Pasteur Institute IRB or the French Office for
Safety in Data Meaning (CNIL).
Sample size
Based on previous studies showing a recovery rate of be-
tween 50 and 88%, we can assume a likelihood of nutri-
tional recovery in the control arm of approximately 60%
after 12 weeks. To show a benefit of at least 15% with
antibiotics or prebiotics, with a type I error of 0.017
(Bonferroni correction for multiple comparisons), a
power of 90% and a two-sided test, 840 children will be
enrolled (280 per arm), with 210 in each country (with
an allowance to loss of 10%). After enrollment, in
Senegal, 80 children with MAM will be evaluated and
followed for their cognitive development and ability.
Statistical analysis
The primary endpoint will be analyzed using both the
intention-to-treat population (children lost to follow-up
or referred at hospital considered as failures) and the per-
protocol population (including only children without
protocol deviation). A third analysis will be conducted
using the last value available (endpoint analysis). A
chi-squared test will be used to compare the primary end-
point (recovery at 3 months) between the three groups.
To take into account the time to recovery, a survival
analysis will be performed using a Cox model with ad-
justment for center and age. Comparisons will be also
performed for the other anthropometric criteria (weight,
height, MUAC, weight gain) as well as for a DMC II test
using a mixed linear model for repeated measurements.
Bioinformatic analysis
For the stool samples, bioinformatics analysis will be con-
ducted to identify the species present in each sample. As
many species can exist in the same sample, samples will be
clustered in “profiles” of composition using principal com-
ponent analysis. In the first step, these profiles will be con-
sidered classes of a parameter called “microbiota.” However,
some specific species could impact the renutrition process
more deeply. A second round of analysis will be conducted
using the species themselves, taking into account the com-
parison of groups of children with rapid versus slow recov-
ery. At the time of inclusion (day 0), analysis will focus on
(1) comparison of microbiota between countries, (2) associ-
ation of some socioeconomic parameters with some specific
profile of microbiota (all countries together), and (3) differ-
ences in microbiota between children with or without mal-
nutrition (for children aged over 18 months). During the
time course of the renutrition process, comparison of
microbiota will be done (1) between the arms of treatment,
(2) between children with and without recovery, and (3) be-
tween children with slow and fast recovery.
Discussion
Child malnutrition is a major public health problem in in-
tertropical zones, but most of the resources and studies
focus on SAM due to its life-threatening impact. However,
SAM develops most often with chronic malnutrition that
can lead to moderate acute malnutrition during shortening
of family resources or during child infections, before wors-
ening into SAM. MAM thus has a heavy impact on national
health structures, as the number of children involved is usu-
ally higher than that for SAM, and acting effectively on
MAM could prevent having to treat more SAM. The delay
in seeking treatment is also often long, causing the situation
to worsen and complicating treatment. Compliance to treat-
ment is also a challenge. Facing these problems, almost no
change in the strategy of treatment has been validated for
the last 30 years. Decreasing the time of treatment and im-
proving the efficacy could be major achievements.
MAM occurrence is almost exclusively restricted to the
first 24 months of life, closely relating to the time when
foods complementary to breast milk are introduced. How-
ever, recent studies on gut physiology have drawn attention
to the role of dis-equilibrated gut microbiota both in mal-
nutrition and obesity. We decided to use two strategies
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(prebiotics and antibiotics) to modulate the microbiota
while providing renutrition with flours.
A short-term effect of antibiotics on nutritional recovery
rate was observed in children treated for severe malnutri-
tion. The effect on MAM could be similar. On the other
hand, prebiotics serve as substrates and induce prolifera-
tion of bifidobacteria and lactobacilli, changing the
proportions of different groups of bacteria in the gut.
Other strategies could be envisioned, such as the use of
anti-oxidants, specific micronutrients, etc.
Overall, we currently have only a partial understanding
of interactions between nutrients, gut microorganisms
and the immune system. Thus, we have chosen a prag-
matic approach for the MALINEA study with two strat-
egies targeting the gut microbiota in a broad manner.
They are safe and practical to use at the community
level in LMICs. Considering the large number of
children concerned, criteria such as low prices, ease of
use, and potential availability of local production, are
very important for the choice of a strategy.
This three-armed randomized intervention will be
evaluated by effects both on the children’s anthropomet-
ric parameters and on their microbiota, providing first
insights into the underlying mechanisms linking MAM,
nutritional recovery and microbiota composition. This
study received approval from the National Ethic Com-
mittees of the four host countries as well as from the In-
ternal Review Board of the Pasteur Institute in Paris.
Trial status
ClinicalTrials.gov, ID: NCT03474276 Last update on 28
May 2018.
Additional file
Additional file 1: Standard Protocol Items: Recommendations for
Interventional Trials (SPIRIT) 2013 Checklist: recommended items to
address in a clinical trial protocol and related documents*. (DOC 122 kb)
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